ACC.15: Late breakers cover latest on TAVR, PCI and more

The American College of Cardiology (ACC) released its lineup for late-breaking clinical trials for its 2015 scientific session. The conference runs March 14-16 in San Diego.

On Saturday, March 14:

• A Randomized Comparison of Anatomic versus Functional Diagnostic Testing Strategies in Symptomatic Patients with Suspected Coronary Artery Disease: Results from the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of chest pain)
• Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS) -Thrombolysis in Myocardial Infarction (TIMI) 54

On Sunday, March 15:

• Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes (OSLER-1 and -2)
• The EMBRACE STEMI Study: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia on Reperfusion Injury in Patients Treated with Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction (EMBRACE STEMI)
• A Randomized, Open-Label, Multi-Center, Active-Controlled, Parallel Group Study To Determine the Efficacy and Safety of the REG1 Anticoagulation System Compared to Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention (REGULATE-PCI)
• Computed Tomography Coronary Angiography In Patients With Suspected Angina Due To Coronary Heart Disease (The SCOT-HEART Trial)
• Economic Comparison of Anatomic Versus Functional Diagnostic Testing Strategies in Symptomatic Patients with Suspected CAD: Results from the PROspective Multicenter Imaging Study for Evaluation of chest pain (PROMISE) Trial
• Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of the PARTNER 1 Trial
• A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed at Increased Risk for Surgery 2-Year Outcomes (CoreValve US Pivotal High Risk Trial)
• Early Clinical and Echocardiographic Outcomes with the SAPIEN 3 Transcatheter Aortic Valve Replacement System in Inoperable, High-Risk and Intermediate-Risk Aortic Stenosis Patients
• First Report of the DEFLECT III Trial Results: A Prospective Randomized Evaluation of The TriGuardTM HDH Embolic DEFLECTion Device During Transcatheter Aortic Valve Replacement
• Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the United States

On Monday, March 16:

• Ablation vs. Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted device: Results from the AATAC Multicenter Randomized Trial
• Effectiveness of Surgical Ablation of Atrial Fibrillation during Mitral Valve Surgery: A Randomized Clinical Trial from the Cardiothoracic Surgical Trials Network
• Long-Term Effect of Goal Directed Weight Management on an Atrial Fibrillation Cohort: A 5-Year Follow-Up Study (LEGACY Study)
• Everolimus-Eluting Stents versus Bypass Surgery for Multivessel Coronary Artery Disease (BEST)
• Effect of Remote Ischemic Preconditioning on Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Graft Surgery: A Multi-Center Randomized Controlled Clinical Trial
• The Total Trial: A Randomized Trial Of Routine Aspiration Thrombectomy With Percutaneous Coronary Intervention (PCI) Versus PCI Alone In Patients With St-elevation Myocardial Infarction Undergoing Primary PCI
• Transradial Versus Transfemoral Access In Patients With Acute Coronary Syndromes Undergoing Invasive Management: Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation Of Angiox (matrix) Access Site Program
• Bivalirudin Infusion Compared To Unfractionated Heparin In Patients With Acute Coronary Syndromes Undergoing Invasive Management: Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation Of Angiox (matrix) Anti-thrombin Program
• The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: PRImary PCI in MULTIvessel Disease

Stay tuned for more details on these trials as the conference nears.